Prednisolone Alternatives Compared
Prednisolone | Vumerity | Copaxone |
|
---|
Prednisolone | Vumerity (diroximel fumarate) | Copaxone (glatiramer) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prednisolone effectively controls inflammation and an overactive immune system but may not be suitable for everybody. Long-term use is limited by potentially severe side effects such as adrenal... View more |
Prescription only
Vumerity (generic name: diroximel fumarate) is an oral prescription medicine indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is given as a twice-daily medicine... View more |
Prescription only
Copaxone is a combination of four amino acids that may be given to treat relapsing forms of multiple sclerosis in adults. It has been shown to significantly reduce the number of relapses, but may be... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
More about Prednisolone | More about Vumerity (diroximel fumarate) | More about Copaxone (glatiramer) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Prednisolone has an average rating of 6.4 out of 10 from a total of 48 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 26% reported a negative effect. |
Vumerity has an average rating of 9.4 out of 10 from a total of 6 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Copaxone has an average rating of 7.6 out of 10 from a total of 133 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 16% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: prednisolone side effects in more detail. |
See also: Vumerity side effects in more detail. |
See also: Copaxone side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
||||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all prednisolone prices |
View all Vumerity prices |
View all Copaxone prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Millipred, Millipred DP, Orapred ODT, PediaPred |
N/A |
Other glatiramer brands include: Glatopa | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
4 hours |
1 hour |
1 hour |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 589 drugs are known to interact with prednisolone:
|
A total of 618 drugs are known to interact with Vumerity:
|
A total of 1 drugs are known to interact with Copaxone:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
October 29, 2019 |
December 20, 1996 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.